BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 19393711)

  • 1. National paediatric immunization program of high risk groups: no effect on the incidence of invasive pneumococcal diseases.
    Rendi-Wagner P; Paulke-Korinek M; Kundi M; Burgmann H; Georgopoulos A; Vécsei A; Kollaritsch H
    Vaccine; 2009 Jun; 27(30):3963-8. PubMed ID: 19393711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective surveillance of incidence, serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae among hospitalized children in Austria.
    Rendi-Wagner P; Georgopoulos A; Kundi M; Mutz I; Mattauch M; Nowak J; Mikolasek A; Vecsei A; Kollaritsch H
    J Antimicrob Chemother; 2004 May; 53(5):826-31. PubMed ID: 15073163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiology and evolution of invasive pneumococcal disease caused by multidrug resistant serotypes of 19A in the 8 years after implementation of pneumococcal conjugate vaccine immunization in Dallas, Texas.
    Techasaensiri C; Messina AF; Katz K; Ahmad N; Huang R; McCracken GH
    Pediatr Infect Dis J; 2010 Apr; 29(4):294-300. PubMed ID: 19949357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Epidemiological features of invasive pneumococcal disease before and after the introduction of pneumococcal conjugate vaccine in Gran Canaria (Canary Islands)].
    Artiles F; Horcajada I; Cañas AM; Alamo I; Bordes A; González A; Santana M; Lafarga B
    Enferm Infecc Microbiol Clin; 2009 Jan; 27(1):14-21. PubMed ID: 19217998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of invasive pneumococcal disease in the Czech Republic and serotype coverage by vaccines, 1997-2006.
    Motlova J; Benes C; Kriz P
    Epidemiol Infect; 2009 Apr; 137(4):562-9. PubMed ID: 18796171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotype distribution of Streptococcus pneumoniae isolated from patients with invasive pneumococcal disease in Brazil before and after ten-pneumococcal conjugate vaccine implementation.
    dos Santos SR; Passadore LF; Takagi EH; Fujii CM; Yoshioka CR; Gilio AE; Martinez MB
    Vaccine; 2013 Dec; 31(51):6150-4. PubMed ID: 23747454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine.
    Black S; France EK; Isaacman D; Bracken L; Lewis E; Hansen J; Fireman B; Austrian R; Graepel J; Gray S; Klein NP
    Pediatr Infect Dis J; 2007 Sep; 26(9):771-7. PubMed ID: 17721369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany.
    Rückinger S; van der Linden M; Reinert RR; von Kries R; Burckhardt F; Siedler A
    Vaccine; 2009 Jun; 27(31):4136-41. PubMed ID: 19406190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study.
    Kellner JD; Vanderkooi OG; MacDonald J; Church DL; Tyrrell GJ; Scheifele DW
    Clin Infect Dis; 2009 Jul; 49(2):205-12. PubMed ID: 19508165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology of invasive pneumococcal disease in the Arabian Peninsula and Egypt.
    Shibl A; Memish Z; Pelton S
    Int J Antimicrob Agents; 2009 May; 33(5):410.e1-9. PubMed ID: 18976887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups.
    Byington CL; Samore MH; Stoddard GJ; Barlow S; Daly J; Korgenski K; Firth S; Glover D; Jensen J; Mason EO; Shutt CK; Pavia AT
    Clin Infect Dis; 2005 Jul; 41(1):21-9. PubMed ID: 15937758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway.
    Vestrheim DF; Løvoll O; Aaberge IS; Caugant DA; Høiby EA; Bakke H; Bergsaker MR
    Vaccine; 2008 Jun; 26(26):3277-81. PubMed ID: 18456376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Herd immunity and pneumococcal conjugate vaccine: a quantitative model.
    Haber M; Barskey A; Baughman W; Barker L; Whitney CG; Shaw KM; Orenstein W; Stephens DS
    Vaccine; 2007 Jul; 25(29):5390-8. PubMed ID: 17583392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme.
    Ingels H; Rasmussen J; Andersen PH; Harboe ZB; Glismann S; Konradsen H; Hoffmann S; Valentiner-Branth P; Lambertsen L;
    Vaccine; 2012 Jun; 30(26):3944-50. PubMed ID: 22504662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine.
    Muñoz-Almagro C; Jordan I; Gene A; Latorre C; Garcia-Garcia JJ; Pallares R
    Clin Infect Dis; 2008 Jan; 46(2):174-82. PubMed ID: 18171247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inferring the potential success of pneumococcal vaccination in Italy: serotypes and antibiotic resistance of Streptococcus pneumoniae isolates from invasive diseases.
    Pantosti A; Boccia D; D'Ambrosio F; Recchia S; Orefici G; Moro ML; ;
    Microb Drug Resist; 2003; 9 Suppl 1():S61-8. PubMed ID: 14633369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasive pneumococcal disease among children in a health district of Barcelona: early impact of pneumococcal conjugate vaccine.
    Calbo E; Díaz A; Cañadell E; Fábrega J; Uriz S; Xercavins M; Morera MA; Cuchi E; Rodríguez-Carballeira M; Garau J;
    Clin Microbiol Infect; 2006 Sep; 12(9):867-72. PubMed ID: 16882291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive pneumococcal disease in England and Wales: vaccination implications.
    Sleeman K; Knox K; George R; Miller E; Waight P; Griffiths D; Efstratiou A; Broughton K; Mayon-White RT; Moxon ER; Crook DW; ;
    J Infect Dis; 2001 Jan; 183(2):239-246. PubMed ID: 11120930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.
    Lacapa R; Bliss SJ; Larzelere-Hinton F; Eagle KJ; McGinty DJ; Parkinson AJ; Santosham M; Craig MJ; O'Brien KL
    Clin Infect Dis; 2008 Aug; 47(4):476-84. PubMed ID: 18627249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in the composition of the pneumococcal population and in IPD incidence in The Netherlands after the implementation of the 7-valent pneumococcal conjugate vaccine.
    Elberse KE; van der Heide HG; Witteveen S; van de Pol I; Schot CS; van der Ende A; Berbers GA; Schouls LM
    Vaccine; 2012 Dec; 30(52):7644-51. PubMed ID: 22521844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.